Tigecycline: A review of a new glycylcycline antibiotic

@article{Scheinfeld2005TigecyclineAR,
  title={Tigecycline: A review of a new glycylcycline antibiotic},
  author={Noah S. Scheinfeld},
  journal={Journal of Dermatological Treatment},
  year={2005},
  volume={16},
  pages={207 - 212}
}
  • N. Scheinfeld
  • Published 1 January 2005
  • Medicine
  • Journal of Dermatological Treatment
Tigecycline derived from minocycline. It is part of a new class of antibiotics called glycylcyclines. Tigecycline is given intravenously and has activity against a variety of gram‐positive and gram‐negative bacterial pathogens, many of which are resistant to existing antibiotics. Tigecycline successfully completed phase III trials in which it was at least equal to intravenous vancomycin and aztreonam to treat complicated skin and skin structure infections (cSSSI), and to intravenous imipenem… Expand
Tigecycline: a glycylcycline antimicrobial agent.
TLDR
In clinical trials, tigecycline was effective for the treatment of complicated skin and skin-structure infections and complicated intra-abdominal infections and its clinical efficacy and tolerability profile was generally well tolerated. Expand
The recent evolution of therapeutic weapons
  • 2015
Introduction Recibido: 06/05/2008 Aceptacion: 12/05/2008 Multiresistant Gram-positive cocci, including Staphylococcus aureus, the group of coagulase-negative staphylococci, Enterococcus faecalis andExpand
Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline
TLDR
Tigecycline is a novel extended-spectrum minocycline derivative that circumvents bacterial resistance, as it is unaffected by efflux pumps and ribosomal protection but should not be used as empiric monotherapy for treatment of health-care associated infections known or suspected to be owing to Pseudomonas aeruginosa or Proteus spp. Expand
The recent evolution of therapeutic weapons against resistant Gram-positive microorganisms La evolución reciente de las armas terapéuticas contra los microorganismos Gram-positivos
TLDR
The main problems related to the epidemiology of multiresistant gram-positive infection, the potential clinical indications of all recently available compounds compared with the standard of care of treatment of resistant Grampositive infections, and updated data on efficacy and tolerability of all these compounds, are updated and outlined on the ground of a review of recent literature evidences. Expand
LEUKOPENİA RELATED TO TİGECYCLİNE USE FOR DİABETİC FOOT INFECTİON: CASE REPORT
Aim: Antibiotics for diabetic foot and foot infections must be chosen according to interpretation of antibiograms and adverse effects of antibiotics must be well-known. Here, we aim to focus onExpand
Emergence of In-Vitro Colistin and / or Tigecycline resistance among Carbapenemase producing Gram negative Bacteria in nosocomial set up
Resistance to Tigecycline and/or Colistin among nosocomial pathogens is an emerging problem. Objective of the study was to record the drug susceptibility pattern of carbapenemase producing gramExpand
Non-antimicrobial strategies for the prevention and treatment of infections by multidrug-resistant gram-negative bacilli
TLDR
In vivo, AOA-2 in combination with colistin reduced bacterial spleen and lung loads, bacteremia and mortality rates, in comparison with the monotherapy with colistsin, and in vivo, the therapeutic efficacy of Aoa-2 against A. baumannii and P. aeruginosa in experimental murine models of peritoneal sepsis and pneumonia was evaluated. Expand
Penicillins, cephalosporins, other β-lactam antibiotics, and tetracyclines
TLDR
Hematotoxicity associated with minocycline recently has been reviewed, covering data reported to a WHO Center for International Drug Monitoring, which had recorded 8025 reactions to minocy Cline, of which 493 were reactions involving the liver. Expand
Tetracyclines: what a rheumatologist needs to know?
  • S. Attar
  • Medicine
  • International journal of rheumatic diseases
  • 2009
TLDR
The rheumatological use of tetracycline and its analogues in rheumatic diseases is reviewed. Expand
Natural product derived promising anti-MRSA drug leads: A review.
TLDR
This review underlines the structures and anti-MRSA activity of various natural product derivatives covering recent reports, in vivo activities and brief Structure Activity Relationships (SARs). Expand
...
1
2
3
...

References

SHOWING 1-10 OF 40 REFERENCES
Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates
TLDR
The new glycylcycline exhibited excellent activity against all gram-positive cocci and was also very potent against most members of the Enterobacteriaceae. Expand
In Vitro Activities of Tigecycline against the Bacteroides fragilis Group
TLDR
Tigecycline was more active than clindamycin, minocycline, trovafloxacin, and cefoxitin and less active than imipenem or piperacillin-tazobactam against all isolates of the B. fragilis group. Expand
Activity of Tigecycline (GAR-936) against Acinetobacter baumannii Strains, Including Those Resistant to Imipenem
TLDR
These in vitro results show that tigecycline has good in vitro bacteriostatic activity against A. baumannii, including strains resistant to imipenem. Expand
The glycylcyclines: a comparative review with the tetracyclines.
TLDR
Tigecycline appears to be a promising new antibacterial based on in vitro and pharmacokinetic/pharmacodynamic activity; however more clinical data are needed to fully evaluate its potential. Expand
Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.
Tigecycline is a novel 9-t-butylglycylamido derivative of minocycline that has demonstrated activity against a variety of Gram-positive and -negative bacterial pathogens. In vitro activity ofExpand
In Vitro Activities of Tigecycline (GAR-936) and 12 Other Antimicrobial Agents against 90 Eikenella corrodens Clinical Isolates
ABSTRACT The activity of tigecycline was compared with those of other antimicrobials against 90 isolates of Eikenella corrodens. The MIC at which 90% of the isolates were inhibited was 2 μg/ml forExpand
In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of Macrolide and Tetracycline Resistance
TLDR
Tigecycline proved to be very active against all the isolates tested, including those resistant to tetracycline, including the resistant to erythromycin-resistant streptococci. Expand
Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects
TLDR
Tigecycline exhibits linear pharmacokinetics and is safe and well tolerated in the dose ranges examined, and side effects, mainly nausea and vomiting, were seen in these studies. Expand
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
TLDR
It is confirmed that tigecycline maintains a truly broad spectrum like the tetracycline class while enhancing potency, making it an attractive candidate for continued clinical development against pathogens causing serious community-acquired respiratory tract infections, as well as cutaneous infections. Expand
Approaches to vancomycin-resistant enterococci.
TLDR
Treatment of vancomycin-resistant enterococci continues to be problematical although these new drugs offer some hope, and the rational use of antibiotics, strict guidelines for the use of new compounds, and adherence to infection control practices continue to be essential components of the management ofVancomycus-resistantEnterococci colonization and infection. Expand
...
1
2
3
4
...